NorthCrest Asset Manangement LLC Has $250,000 Stock Position in GSK plc (NYSE:GSK)

NorthCrest Asset Manangement LLC trimmed its position in GSK plc (NYSE:GSK - Free Report) by 98.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,392 shares of the pharmaceutical company's stock after selling 376,196 shares during the quarter. NorthCrest Asset Manangement LLC's holdings in GSK were worth $250,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock worth $1,786,475,000 after acquiring an additional 23,814,104 shares during the last quarter. Primecap Management Co. CA lifted its stake in GSK by 70.1% in the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock valued at $854,349,000 after purchasing an additional 10,407,905 shares during the last quarter. Voloridge Investment Management LLC lifted its stake in GSK by 1,360.4% in the 4th quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock valued at $73,222,000 after purchasing an additional 2,016,795 shares during the last quarter. Bridgewater Associates LP boosted its position in GSK by 132.7% in the fourth quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company's stock valued at $76,017,000 after buying an additional 1,281,855 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in shares of GSK during the fourth quarter worth $36,665,000. 15.74% of the stock is owned by institutional investors.

Analyst Ratings Changes

GSK has been the topic of several recent research reports. Wall Street Zen downgraded GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. BNP Paribas assumed coverage on GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target on the stock. Hsbc Global Res upgraded GSK to a "strong sell" rating in a report on Monday, April 28th. Morgan Stanley assumed coverage on shares of GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday. One analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $37.38.

GSK Trading Up 0.9%

GSK stock traded up $0.37 during mid-day trading on Wednesday, hitting $40.83. 2,939,738 shares of the stock were exchanged, compared to its average volume of 4,836,574. GSK plc has a 12 month low of $31.72 and a 12 month high of $44.67. The firm's fifty day simple moving average is $37.48 and its two-hundred day simple moving average is $36.28. The stock has a market capitalization of $84.24 billion, a price-to-earnings ratio of 25.68, a PEG ratio of 1.12 and a beta of 0.51. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The firm had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The business's revenue was up 2.1% compared to the same quarter last year. During the same period last year, the business posted $0.43 EPS. Analysts forecast that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a $0.4216 dividend. The ex-dividend date of this dividend is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.13%. GSK's payout ratio is 86.60%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.